Patients with colon cancer and obesity treated with GLP-1 receptor agonists (GLP-1 drugs) had lower mortality compared to other patients[3]. A retrospective cohort study showed a consistent trend with fewer serious non-cancer complications in these patients[1]. A study indicates a significant reduction in mortality in patients taking drugs such as Ozempic or Wegovy[3]. In patients with type 2 diabetes without cancer at baseline, the odds of developing colon cancer were 44% lower with GLP-1 RA versus insulin[2]. Among approximately 22,600 people on insulin, there were 167 cases of colon cancer, compared to only 94 cases in the same number on GLP-1 RA[2]. GLP-1 RAs were associated with a lower risk of 10 of 13 obesity-related cancers compared to insulin[1].